A Randomized Phase 2 Study of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Erlotinib (Primary) ; Tivantinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 28 Apr 2012 Planned number of patients changed from 154 to 193 as reported by European Clinical Trials Database record.
- 29 Mar 2012 Results will be presented at AACR-2012 according to an ArQule media release. Results were also summarised in the media release.
- 18 Jul 2011 Results published in the Journal of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History